The Lack of Follow-Up, a Major Factor in Smoking Cessation Failure

Smoking cessation remains a complex challenge in community pharmacy practice. Nicotine dependence, behavioral components, and the psychosocial context are all dimensions that must be considered, and which nicotine replacement therapy alone cannot fully address. In response to this observed reality, the Cooperation for the Valorization of the Pharmaceutical Act (CVAO) has developed a structured recommendation focused on precise titration of nicotine substitutes and individualized patient follow-up. Dr. Valentin Legrand, a community pharmacist in the Nantes region and president of CVAO, elaborates on the practical implications for pharmacy teams.

The CVAO: Fostering Discussion and Innovation in Pharmacy

The Cooperation for the Valorization of the Pharmaceutical Act (CVAO) was established to create a vital platform for dialogue among pharmacists, pharmacy students, and pharmacy technicians. Crucially, it extends this collaborative space to include other healthcare professionals and, significantly, the end-users of pharmaceutical services. The overarching ambition of CVAO is to function as a genuine incubator for new ideas and innovative practices within the pharmacy sector. The organization is dedicated to enhancing the value and perception of community pharmacy by highlighting its inherent humanistic and forward-thinking dimensions. CVAO advocates for a vision of the pharmacy as a holistic health hub where individuals receive care and support, rather than merely a transactional point for dispensing medications. A key focus of their work also involves strengthening the collaborative networks between various healthcare professionals, aiming to ensure a more responsive and effective approach to meeting the genuine needs of the public.

Addressing the Gaps in Smoking Cessation Support

Dr. Legrand explained that the impetus for CVAO’s focused work on smoking cessation stemmed from a very tangible observation in everyday pharmacy practice: the current support provided to smoking patients is frequently insufficient. He highlighted a concerning trend of the widespread dispensing of high-dose transdermal patches, which are often not adequately matched to the patient’s specific level of dependence. This mismatch can lead to discouragement, with many patients concluding that nicotine replacement therapies (NRTs) are ineffective.

"In reality," Dr. Legrand stated, "these devices alone cannot address all the multifaceted aspects of smoking. Smoking is not solely about nicotine dependence; it often serves as a personal moment, an escape, or a social ritual." The pharmacist, he emphasized, is ideally positioned to support these patients. "We are accessible," he continued, "we see the same individuals regularly, and we gain an understanding of their environment, social lives, and habits. These are essential levers for tailoring the support provided."

The CVAO’s recommendations also emerge within a broader context of ongoing experimentation with smoking cessation strategies. Notably, concurrent, though independent, initiatives are underway in the Hauts-de-France region, further underscoring the national focus on improving cessation outcomes.

Genesis of the "Pharmacy Team Partner to the Smoker Patient" Recommendation

The initiative to develop the "Pharmacy Team Partner to the Smoker Patient" recommendation was formally launched at Pharmagora 2025. During this event, initial findings from existing literature were presented to raise professional awareness and to recruit participants for a dedicated working group. This group, comprising eleven individuals – including community pharmacists, pharmacy students, and a general practitioner – drew upon a robust foundation of evidence. Their research incorporated data from the French National Food, Environmental and Occupational Health and Safety Agency (Anses), barometer surveys from Public Health France, recommendations from the High Authority of Health (HAS), and extensive scientific literature.

"From these elements," Dr. Legrand explained, "we identified key observations, highlighted connections that needed to be made in practice, and then constructed concrete recommendations." The resulting document underwent a thorough review and validation process by an addiction specialist and a tobacco cessation physician, ensuring its clinical accuracy and practical applicability.

The Core Philosophy: Precise Titration and Personalized Support

The fundamental principle underpinning CVAO’s recommendation is the precise titration of a patient’s nicotine consumption. "The objective is simple," Dr. Legrand articulated. "To adapt the dose to reduce the risk of failure, and then to support a gradual decrease, at the patient’s own pace."

However, he stressed that beyond the pharmacological aspect, comprehensive support is paramount. "Literature consistently shows that a lack of follow-up significantly contributes to relapses and diminishes the overall effectiveness of cessation efforts. Without adequate support, the medico-economic benefits of treatments are limited, as cessation failures lead to continued smoking and the associated costs of tobacco-related diseases."

Consequently, the recommendation strongly advocates for individualized patient management. "This is not about applying standardized protocols," Dr. Legrand asserted. "Each patient is unique. It is essential to evaluate their level of dependence, their motivation – which is a key factor – and to monitor symptoms and adverse effects related to cessation, such as persistent cough, which can be misunderstood and become discouraging."

Repositioning the Pharmacy as a Hub for Care

This structured approach aims to reposition the community pharmacy as a central location for ongoing care and support. The recommendation seeks to establish a genuine patient journey, where individuals do not merely come to acquire a health product but to seek sustained accompaniment and encouragement.

"The pharmacist becomes the one who ‘holds their hand’," Dr. Legrand described, "who offers encouragement and helps them see the process through to the end. We champion the idea that the pharmacy is a complete health space, delivering not only pharmacological value but also significant human value." The paradigm shift, he concluded, moves away from simply instructing patients on what they should do, towards empowering them to become active participants in managing their own health and well-being.

Supporting Data and Broader Context

The effectiveness of comprehensive smoking cessation programs, which include both pharmacological support and behavioral counseling, has been well-documented. Studies have consistently shown that individuals who receive regular follow-up and personalized support are significantly more likely to achieve long-term abstinence from smoking compared to those who do not. For instance, a meta-analysis published in the Cochrane Database of Systematic Reviews indicated that behavioral support, in addition to pharmacotherapy, can double the chances of successful quitting.

The economic implications of smoking cessation are also substantial. The World Health Organization (WHO) estimates that tobacco use is a leading cause of preventable death and disease globally, resulting in trillions of dollars in healthcare costs and lost productivity each year. In France, while specific figures for the economic burden of smoking cessation failures are difficult to isolate, the overall cost associated with tobacco-related illnesses, including cardiovascular diseases, respiratory conditions, and various cancers, is estimated to be in the tens of billions of euros annually. By improving cessation rates, pharmacies can play a crucial role in reducing this burden.

The Role of the Pharmacist in Public Health

Pharmacists are increasingly recognized as integral members of the healthcare team, extending beyond dispensing to offering a range of clinical services. Their accessibility and frequent patient interactions make them uniquely positioned to identify individuals at risk, provide preventive advice, and manage chronic conditions, including supporting smoking cessation. In France, the framework for pharmaceutical practice has evolved to formalize and remunerate such services, encouraging pharmacists to take a more proactive role in public health initiatives.

The CVAO’s recommendation aligns with broader European trends, where pharmacies are being empowered to offer more advanced patient care services. Initiatives aimed at improving medication adherence, managing chronic diseases, and promoting healthy lifestyles are becoming standard practice in many member states.

Potential for Wider Impact and Future Directions

The CVAO’s structured approach to smoking cessation has the potential to significantly impact public health outcomes in France. By providing pharmacists with clear guidelines and a framework for personalized patient care, the initiative can lead to higher success rates in quitting smoking. This, in turn, can translate into a reduction in smoking-related morbidity and mortality, as well as a decrease in the associated healthcare expenditures.

The emphasis on individualized support and the recognition of the psychological and social aspects of smoking are critical. This holistic approach acknowledges that quitting is not just a physical process but a significant behavioral and emotional journey. By fostering a more supportive and understanding environment within the pharmacy, patients are more likely to feel empowered and motivated to persevere through challenges.

Future directions for this initiative could include the development of digital tools to support pharmacists in patient follow-up, the integration of smoking cessation services with other public health programs, and further research to evaluate the long-term effectiveness and cost-effectiveness of the CVAO’s recommended approach. Collaboration with public health agencies, insurance providers, and patient advocacy groups will be crucial in scaling up these efforts and ensuring their widespread adoption. The continued professional development of pharmacists in behavioral counseling and addiction support will also be a key factor in maximizing the success of these vital public health interventions.